CN109562176A - 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 - Google Patents

使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 Download PDF

Info

Publication number
CN109562176A
CN109562176A CN201780037696.7A CN201780037696A CN109562176A CN 109562176 A CN109562176 A CN 109562176A CN 201780037696 A CN201780037696 A CN 201780037696A CN 109562176 A CN109562176 A CN 109562176A
Authority
CN
China
Prior art keywords
cancer
group
cell
egfr tki
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780037696.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·维连奇克
M·弗里德
A·库兹涅佐娃
Y·甘金
M·杜伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Felicitex Therapeutics Inc
Original Assignee
Felicitex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Felicitex Therapeutics Inc filed Critical Felicitex Therapeutics Inc
Publication of CN109562176A publication Critical patent/CN109562176A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780037696.7A 2016-04-15 2017-04-14 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合 Pending CN109562176A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323537P 2016-04-15 2016-04-15
US62/323537 2016-04-15
PCT/US2017/027719 WO2017181075A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Publications (1)

Publication Number Publication Date
CN109562176A true CN109562176A (zh) 2019-04-02

Family

ID=60039950

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780037696.7A Pending CN109562176A (zh) 2016-04-15 2017-04-14 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合

Country Status (11)

Country Link
US (3) US10322128B2 (enExample)
EP (1) EP3442505A4 (enExample)
JP (2) JP7123806B2 (enExample)
KR (2) KR20230020565A (enExample)
CN (1) CN109562176A (enExample)
AU (2) AU2017248762A1 (enExample)
BR (1) BR112018071031A2 (enExample)
CA (1) CA3021021A1 (enExample)
IL (2) IL262323B (enExample)
MX (2) MX2018012511A (enExample)
WO (1) WO2017181075A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947673A (zh) * 2022-12-19 2023-04-11 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009350A1 (en) * 2016-01-05 2017-07-13 The Trustees Of Columbia University In The City Of New York Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein
US10322128B2 (en) 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
CN109313197A (zh) 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
CN113557237B (zh) 2019-01-18 2025-01-14 沃若诺伊公司 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途
WO2020235973A1 (ko) * 2019-05-22 2020-11-26 주식회사 보로노이 암의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
JP2024523861A (ja) * 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
AU2022426699A1 (en) 2021-12-30 2024-07-11 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103797002A (zh) * 2011-08-19 2014-05-14 迪亚克森海特公司 Dyrk1抑制剂及其用途
US20140371251A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
US20150266825A1 (en) * 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells
WO2016055916A1 (en) * 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
WO2017014788A1 (en) * 2015-07-23 2017-01-26 Taipei Medical University Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560004A1 (de) * 2011-08-19 2013-02-20 DST Diagnostische Systeme & Technologien GmbH Neues PoC-Testsystem und Verfahren
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10322128B2 (en) * 2016-04-15 2019-06-18 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors
CN109313197A (zh) 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103797002A (zh) * 2011-08-19 2014-05-14 迪亚克森海特公司 Dyrk1抑制剂及其用途
US20150292032A1 (en) * 2012-10-10 2015-10-15 Felicitex Therapeutics, Inc. Treatment of cancer by targeting quiescent cancer cells
US20140371251A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
US20150266825A1 (en) * 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
WO2016055916A1 (en) * 2014-10-06 2016-04-14 Novartis Ag Therapeutic combination for the treatment of cancer
WO2017014788A1 (en) * 2015-07-23 2017-01-26 Taipei Medical University Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAINA Z. EWTON等: "Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells", 《MOL CANCER THER》 *
DARREN R TYSON等: "Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data", 《NATURE METHODS》 *
FORTUNATO CIARDIELLO等: "The role of EGFR inhibitors in nonsmall cell lung cancer", 《CURRENT OPINION IN ONCOLOGY》 *
KARIKIOS, D. J.等: "Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence", 《CLINICAL INVESTIGATION》 *
LIN,LISHAN等: "Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its Biotransformation", 《DRUG METABOLISM AND DISPOSITION》 *
LUCIA REGALES等: "Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer", 《THE JOURNAL OF CLINICAL INVESTIGATION》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947673A (zh) * 2022-12-19 2023-04-11 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用
CN115947673B (zh) * 2022-12-19 2024-03-15 湖南岳靶生物医药有限公司 一种化疗药物增敏剂、组合物及其应用

Also Published As

Publication number Publication date
CA3021021A1 (en) 2017-10-19
US11202779B2 (en) 2021-12-21
US20220110940A1 (en) 2022-04-14
KR20180132882A (ko) 2018-12-12
BR112018071031A2 (pt) 2019-02-12
MX2023000549A (es) 2023-02-13
IL262323A (en) 2018-11-29
KR20230020565A (ko) 2023-02-10
AU2017248762A1 (en) 2018-11-01
JP7123806B2 (ja) 2022-08-23
IL288777A (en) 2022-02-01
KR102494174B1 (ko) 2023-02-02
JP2019511554A (ja) 2019-04-25
IL262323B (en) 2022-03-01
US20190298723A1 (en) 2019-10-03
JP2022145800A (ja) 2022-10-04
MX2018012511A (es) 2019-07-08
US20170296541A1 (en) 2017-10-19
EP3442505A1 (en) 2019-02-20
US10322128B2 (en) 2019-06-18
EP3442505A4 (en) 2019-12-18
AU2023200428A1 (en) 2023-03-02
WO2017181075A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CN109562176A (zh) 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
Hoang et al. Oncogenic signaling of MEK5-ERK5
Huang et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
Koul et al. Antitumor activity of NVP-BKM120—a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells
Qi et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B‐cell lymphomas
CN109313197A (zh) 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
Xie et al. Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth
CN118338905A (zh) Wee1激酶抑制剂在治疗癌症中的应用
US20230129271A1 (en) Compositions and methods for treating cancer
JP2007513967A (ja) 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
Qin et al. Targeting telomerase enhances cytotoxicity of salinomycin in cancer cells
Lehmann et al. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
Chang HI-511 inhibits both BRAF and AURKB to overcome malignant melanoma drug resistance and metastasis
Liu et al. Involvement of autophagy and apoptosis in studies of anticancer drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190402